Vaccines against influenza A (H5N1): evidence of progress

Editorial

Gregory A Poland et al. J Infect Dis. 2008.

. 2008 Sep 1;198(5):629-31.

doi: 10.1086/590912.

No abstract available

Comment on

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I. Levie K, et al. J Infect Dis. 2008 Sep 1;198(5):642-9. doi: 10.1086/590913. J Infect Dis. 2008. PMID: 18576945 Clinical Trial.
Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ. Goji NA, et al. J Infect Dis. 2008 Sep 1;198(5):635-41. doi: 10.1086/590916. J Infect Dis. 2008. PMID: 18694338 Clinical Trial.